|President and CEO, globally responsible for the company including USA and China operations. Prior to AmbioPharm, Dr. Bai was president and CEO of American Peptide Company building the cGMP manufacturing business for American Peptide Company during his 5 years’ tenure. Prior to American Peptide Company, He was Senior Research and Development Scientist in the Peptide Section at Abbott Laboratories (N. Chicago, IL) where he was responsible for peptide process development, scale up and cGMP manufacturing. He was involved in numerous peptide process development projects and cGMP manufacturing of peptides over a six-year period at Abbott, including the process development and manufacturing of a 22-amino acid peptide on a 40 kg scale by solution phase chemistry.|
Chief Financial Officer of the Ambio Holdings, the parent of Ambio and AmbioPharm. He is responsible for financial reporting, cash management, banking relations, investor relations, and government liaison. Mr. Kiel has served as CFO in five previous and CEO in two prior companies and has consulted to more than 150 businesses. He was a Partner with Deloitte Consulting (a Big Four accounting firm). Mr. Kiel holds an MBA from the Ohio State University and was awarded a CPA and Series 7 license.
As Chief Operating Officer, he is responsible for overall operations for the company in US and China. Since 1993, he has held numerous roles in the development, manufacturing, and business management of both clinical development and commercialization of peptide based therapeutics. He has been involved in the successful commercialization of multiple peptide products, from small gram scale to kilogram scale. Prior to Ambiopharm, he worked at Mallinckrodt Pharmaceuticals, which in addition to the peptide division, his experience also included the management of other small molecule commercial generic products and excipients. He also holds an MBA from Maryville University.
Executive Vice President of Business Development and cGMP Sales. He is responsible for contract manufacturing of synthetic peptides and small molecules to be manufactured under cGMP as generic peptide APIs and API’s for human clinical trials. Since 1995, he has developed and maintained worldwide business relationships with scientists in academia, government and private industry. He has managed over 300 projects involving cGMP grade peptides in scales from grams to kilograms at manufacturing facilities at Peninsula Laboratories, Bachem, American Peptide Company and AmbioPharm.
Vice President of Quality, is responsible for quality assurance and control both in the Company’s China and United States facilities. He has many years’ experience in Quality Control, Quality Assurance, cGMP manufacturing facility qualification and process validation. Prior to AmbioPharm, Dr. Geiger was employed by American Peptide Company and UCB Bioproducts in the area of Business Development and Quality Control.
He is responsible for sales and technical advice for the contract manufacturing of synthetic peptides, pegylated peptides and peptide protein conjugates to be manufactured as either non GMP or cGMP including generic peptide APIs and API’s for human clinical trials. Since 1988, he has developed and maintained worldwide collaborations and business relationships with scientists in academia, government and private industry. He has a publication record of more than 110 peer reviewed papers on the synthesis and development of complex peptides for the treatment of human disease. With a career centered around research and development of peptides, he has participated in numerous programs which evolved into the requirement of cGMP grade peptides at scales from grams to kilograms. Dr Pennington was part of the management team with a 20+ year career at Bachem Bioscience followed by 7+ years as President and CEO at Peptides International.
President, Ambio, Inc., is globally responsible for the company’s operations including North America, Europe, Japan, and China. Dr. Singh has more than 16 years of broad range experience in Analytical R&D, Formulation, Drug Product Development, Regulatory, and Quality Control. He has been a key player in taking multiple complex generic projects from R&D to commercial stage. He also plays key role in strategic partnerships with various large generic pharma companies and CDO/CMO/CRO’s across the world.